Specific neoepitopes involved in eliciting productive immune responses that promote tumor regression either by engaging cellular cytotoxicity or by cytokine production (e.g. IFN-γ) are therefore particularly attractive for developing personalized therapies within the framework of precision cancer medicine (54, 55). The gene discussed is IFNG; the disease is neoplasm.